Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pancreatic Neoplasms × pegfilgrastim × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 21 Lymphoma 19 Neutropenia 13 Lymphoma, Large B-Cell, Diffuse 12 Neoplasms 10 Lymphoma, Non-Hodgkin 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Multiple Myeloma 7 Leukemia 7 Carcinoma, Non-Small-Cell Lung 7 Lymphoma, Follicular 6 Burkitt Lymphoma 6 Leukemia, Lymphocytic, Chronic, B-Cell 5 Sarcoma 4 Lymphoma, Mantle-Cell 4 Lymphoma, Large-Cell, Immunoblastic 4 Lymphoma, B-Cell, Marginal Zone 4 Lung Neoplasms 4 Hodgkin Disease 4 Urinary Bladder Neoplasms 3 Rhabdomyosarcoma 3 Ovarian Neoplasms 3 Chemotherapy-induced Neutropenia 3 Waldenstrom Macroglobulinemia 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms 2 Lymphoma, T-Cell, Peripheral 2 Leukemia, Myeloid, Acute 2

Interventions

Gemcitabine 268 Fluorouracil 72 Oxaliplatin 70 130-nm albumin-bound paclitaxel 59 Leucovorin 51 Capecitabine 48 Radiotherapy 47 Albumin-Bound Paclitaxel 47 Irinotecan 41 Cisplatin 34 Taxes 32 Erlotinib Hydrochloride 32 pembrolizumab 26 Radiosurgery 26 Docetaxel 25 S 1 (combination) 24 Bevacizumab 21 folfirinox 18 Nivolumab 17 Radiation 15 Magnetic Resonance Spectroscopy 15 Cyclophosphamide 15 Cetuximab 15 irinotecan sucrosofate 14 Drug Therapy 12 Surgical Procedures, Operative 11 Specimen Handling 10 Biopsy 10 Paclitaxel 9 Ipilimumab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06094140 2024-12-03

NEO-IMPACT

Australasian Gastro-Intestinal Trials Group

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡